Compounds and compositions for use in the treatment and prevention of lung and brain cancer and precancerous conditions thereof

A method of treating and/or preventing lung or brain cancer and/or precancerous conditions thereof, comprising administering a compound of Formula I

• or an enantiomer, diastereomer, racemate, tautomer, salt or hydrate thereof, wherein:
• A is an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic substituent or alkylaryl substituent having 1 to 100 carbon atoms;
• X1 is selected from the group consisting of —O—, —S— and —NR1—,
• R1 being hydrogen or C1-100-alkyl;
• B is selected from
• a single bond and an aliphatic group with 1 to 100 carbon atoms,
• R2, R4 and R5 being the same or different C1-3-alkylene,
• R3 being hydrogen, C1-6-alkyl, halogenated C1-6-alkyl;
• C1-6-alkoxy, halogenated C1-6-alkoxy, —C(O)—C1-6-alkyl, —C(O)O—C1-6-alkyl, —OC(O)—C-1-6-alkyl, —C(O)NH2, —C(O)NH—C1-6-alkyl, —S(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, —S(O)2NH—C1-6-alkyl, cyano, halo or hydroxyl;
• Z is selected from
• and a folic acid residue;
• R6 being independently selected from hydrogen, C1-100-alkyl, and a polyethylene glycol residue,
• R7 being independently selected from hydrogen, C1-100-alkyl, and a polyethylene glycol residue;
• or
• B together with Z forms a structure:
• R6 being defined as above, and
• R8 being independently selected from hydrogen, an aliphatic substituent with 1 to 22 carbon atoms, and a polyethylene glycol residue;
• to a human or animal by the respiratory route.